日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Purine nucleoside phosphorylase enables dual metabolic checkpoints that prevent T cell immunodeficiency and TLR7-associated autoimmunity

嘌呤核苷磷酸化酶能够实现双重代谢检查点,从而预防T细胞免疫缺陷和TLR7相关的自身免疫性疾病。

Abt, Evan R; Rashid, Khalid; Le, Thuc M; Li, Suwen; Lee, Hailey R; Lok, Vincent; Li, Luyi; Creech, Amanda L; Labora, Amanda N; Mandl, Hanna K; Lam, Alex K; Cho, Arthur; Rezek, Valerie; Wu, Nanping; Abril-Rodriguez, Gabriel; Rosser, Ethan W; Mittelman, Steven D; Hugo, Willy; Mehrling, Thomas; Bantia, Shanta; Ribas, Antoni; Donahue, Timothy R; Crooks, Gay M; Wu, Ting-Ting; Radu, Caius G

FLASHForward: plasma wakefield accelerator science for high-average-power applications

FLASHForward:用于高平均功率应用的等离子体尾场加速器科学

D'Arcy, R; Aschikhin, A; Bohlen, S; Boyle, G; Brümmer, T; Chappell, J; Diederichs, S; Foster, B; Garland, M J; Goldberg, L; Gonzalez, P; Karstensen, S; Knetsch, A; Kuang, P; Libov, V; Ludwig, K; Martinez de la Ossa, A; Marutzky, F; Meisel, M; Mehrling, T J; Niknejadi, P; Põder, K; Pourmoussavi, P; Quast, M; Röckemann, J-H; Schaper, L; Schmidt, B; Schröder, S; Schwinkendorf, J-P; Sheeran, B; Tauscher, G; Wesch, S; Wing, M; Winkler, P; Zeng, M; Osterhoff, J

Correction to: The first-in-class alkylating deacetylase inhibitor molecule tinostamustine shows antitumor effects and is synergistic with radiotherapy in preclinical models of glioblastoma

更正:首个烷化脱乙酰酶抑制剂分子替诺司汀在胶质母细胞瘤的临床前模型中显示出抗肿瘤作用,并与放射疗法具有协同作用。

Festuccia, C; Mancini, A; Colapietro, A; Gravina, G L; Vitale, F; Marampon, F; Delle Monache, S; Pompili, S; Cristiano, L; Vetuschi, A; Tombolini, V; Chen, Y; Mehrling, T

The first-in-class alkylating deacetylase inhibitor molecule tinostamustine shows antitumor effects and is synergistic with radiotherapy in preclinical models of glioblastoma

首创的烷基化去乙酰化酶抑制剂分子替诺莫司汀表现出抗肿瘤作用,并在胶质母细胞瘤的临床前模型中与放射治疗具有协同作用

Claudio Festuccia, Andrea Mancini, Alessandro Colapietro, Giovanni Luca Gravina, Flora Vitale, Francesco Marampon, Simona Delle Monache, Simona Pompili, Loredana Cristiano, Antonella Vetuschi, Vincenzo Tombolini, Yi Chen, Thomas Mehrling

Establishment and Characterization of a Reliable Xenograft Model of Hodgkin Lymphoma Suitable for the Study of Tumor Origin and the Design of New Therapies

建立和表征可靠的霍奇金淋巴瘤异种移植模型,适用于研究肿瘤起源和设计新疗法

M'kacher, Radhia; Frenzel, Monika; Al Jawhari, Mustafa; Junker, Steffen; Cuceu, Corina; Morat, Luc; Bauchet, Anne-Laure; Stimmer, Lev; Lenain, Aude; Dechamps, Nathalie; Hempel, William M; Pottier, Geraldine; Heidingsfelder, Leonhard; Laplagne, Eric; Borie, Claire; Oudrhiri, Noufissa; Jouni, Dima; Bennaceur-Griscelli, Annelise; Colicchio, Bruno; Dieterlen, Alain; Girinsky, Theodore; Boisgard, Raphael; Bourhis, Jean; Bosq, Jacques; Mehrling, Thomas; Jeandidier, Eric; Carde, Patrice

Strategy for Assessing New Drug Value in Orphan Diseases: An International Case Match Control Analysis of the PROPEL Study

评估罕见病新药价值的策略:PROPEL 研究的国际病例对照分析

O'Connor, Owen A; Marchi, Enrica; Volinn, Weining; Shi, Jin; Mehrling, Thomas; Kim, Won Seog

Challenges in Optimising the Successful Construction of Antibody Drug Conjugates in Cancer Therapy

优化癌症治疗中抗体药物偶联物成功构建的挑战

Thomas Mehrling, Daniel Soltis

Combined alkylation and histone deacetylase inhibition with EDO-S101 has significant therapeutic activity against brain tumors in preclinical models

EDO-S101 联合烷基化和组蛋白去乙酰化酶抑制作用在临床前模型中对脑肿瘤具有显著的治疗活性。

Qiu, Yushi; Li, Zhimin; Copland, John A; Mehrling, Thomas; Tun, Han W

Preclinical anti-myeloma activity of EDO-S101, a new bendamustine-derived molecule with added HDACi activity, through potent DNA damage induction and impairment of DNA repair

EDO-S101 是一种新型苯达莫司汀衍生分子,具有附加的 HDACi 活性,可通过强效诱导 DNA 损伤和破坏 DNA 修复,发挥临床前抗骨髓瘤活性

Ana-Alicia López-Iglesias, Ana B Herrero, Marta Chesi, Laura San-Segundo, Lorena González-Méndez, Susana Hernández-García, Irena Misiewicz-Krzeminska, Dalia Quwaider, Montserrat Martín-Sánchez, Daniel Primo, Teresa Paíno, P Leif Bergsagel, Thomas Mehrling, Marcos González-Díaz, Jesús F San-Miguel, M

The first-in-class alkylating HDAC inhibitor EDO-S101 is highly synergistic with proteasome inhibition against multiple myeloma through activation of multiple pathways

首个烷基化HDAC抑制剂EDO-S101通过激活多种通路,与蛋白酶体抑制剂对多发性骨髓瘤具有高度协同作用。

Besse, L; Kraus, M; Besse, A; Bader, J; Silzle, T; Mehrling, T; Driessen, C